Drug Metabolism/Transport and Pharmacokinetics |
Autore | Song Im-Sook |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
Descrizione fisica | 1 electronic resource (232 p.) |
Soggetto topico |
Medicine
Pharmaceutical industries |
Soggetto non controllato |
tofacitinib
dose-dependent pharmacokinetics hepatic and intestinal first-pass effect rats catalposide in vitro human metabolism UDP-glucuronosyltransferase sulfotransferase carboxylesterase celecoxib drug–drug interaction fluorescence HPLC metabolism repaglinide HSG4112 anti-obesity agent stereoselectivity pharmacokinetics compound K protopanaxadiol (PPD) biliary excretion intestinal metabolism Carthamus tinctorius extract notoginseng total saponins comparative pharmacokinetic study large volume direct injection compatibility mechanism mertansine human hepatocytes cytochrome P450 UDP-glucuronosyltransferases sodium-glucose cotransporter 2 (SGLT2) inhibitors DWP16001 kidney distribution inhibition mode diabetes transporter-enzyme interplay influx transporter efflux transporter physiologically based pharmacokinetic model cytochrome P450 enzymes tiropramide healthy Korean subjects modeling population pharmacokinetic quercetin breast cancer resistance protein inhibitor prazosin sulfasalazine kinetic analysis food–drug interactions Caco-2 EpiIntestinal first-pass P-gp BCRP drug transporter CYP3A4 oral availability automatization drug absorption drug dosing head-and-neck cancer real-time measurements taxanes tissue engineering UHPLC-MS/MS metformin verapamil drug interaction organic cation transporter 2 renal excretion acute renal failure gentamicin cisplatin hepatic CYP3A1(23) creatinine clearance renal clearance nonrenal clearance |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557607703321 |
Song Im-Sook
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Rheumatoid Arthritis Therapy Reappraisal : Strategies, Opportunities and Challenges |
Autore | Müller Rüdiger |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
Descrizione fisica | 1 electronic resource (260 p.) |
Soggetto topico | Medicine |
Soggetto non controllato |
rheumatoid arthritis
sleep sleep disorders pain osteoporosis fracture fracture risk assessment tool treat-to-target certolizumab pegol csDMARDs glucocorticoids intra-articular injections DAS 28 ACR response HAQ-DI TNFα golimumab efficacy tolerability immunogenicity methotrexate posology titration oral route subcutaneous route bioavailability effectiveness periodontitis periodontal disease anti-citrullinated protein autoantibodies rheumatoid factor smoking medication Porphyromonas gingivalis Rheumatoid arthritis matrix metalloproteinase 3 infliximab pharmacogenomics anti-TNF personalized medicine baricitinib disease-modifying antirheumatic drugs pain perception outcomes research patient perspective Rheumatoid Arthritis therapy DMARD MTX Tumor Necrosis Factor-Alpha Inhibitors ankylosing spondylitis biosimilar switching synovial fibroblasts cytokine osteoclast herbal medicine methylation next-generation sequencing recovery of function fatigue productivity tofacitinib oral Th1.17 IL-17A IFN-γ, CD73 adenosine psoriatic arthritis regulation pseudoerosions hand foot ultrasonography radiography computed tomography magnetic resonance imaging |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Altri titoli varianti | Rheumatoid Arthritis Therapy Reappraisal |
Record Nr. | UNINA-9910557286503321 |
Müller Rüdiger
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|